Number Of Coronary Heart Disease Patients Research Articles

OR20. Correlation between diabetes mellitus and significant in-stent restenosis in patient underwent coronary angiography evaluation

Abstract Aims Percutaneous Coronary Intervention (PCI) is a non-surgical invasive intervention with or without stenting performed on coronary heart disease (CHD) patient to improve blood flow of narrowed coronary arteries. One of the complication after PCI is in-stent restenosis (ISR), which is the narrowing of stented segment of coronary artery. Diabetes Mellitus (DM), is characterized by hyperglycemia, has long been known to increase the risk of CHD by 2-4 fold. Condition of hyperglycemia in diabetes has affects on the progression of neointimal hyperplasia (NIH) that progress to ISR. As the number of CHD patients with diabetes mellitus (DM) is expected to increase, so is the risk of ISR incidence in CHD patients with diabetes mellitus (DM) who undergo PCI. Method and Results A retrospective cross-sectional study was conducted using medical records of CHD patients who underwent coronary angiography evaluation between January 2018 and March 2020 at Catheterization Laboratory, Regional General Hospital of West Nusa Tenggara. Significant ISR was defined as diameter of stenosis ≥50% at coronary angiography evaluation. Total subjects were 66 subjects, with 33 DM subjects and 33 non-DM subjects, and ISR was found in 12 and 10 subjects respectively. There was no significant difference on the incidence of ISR between the DM and non-DM groups. Conclusion There was no correlation between DM and ISR, and there was no significant difference in the incidence of ISR between the DM and non-DM group in CHD subjects underwent coronary angiography evaluation.

FIVE YEAR PROGNOSIS IN PATIENTS WITH CORONARY HEART DISEASE AND COMORBIDITIES: DATA FROM MULTICENTER STUDY IN INGUSHETIA REPUBLIC

Aim. Analysis of the primary endpoints occurence in male and female cohort of coronary heart disease (CHD) patients comorbid with other somatic pathology, during 5 years. Material and methods. To the study, 320 patients included (143 males, 177 females, age 46-72 y. o.) with CHD stable angina I-III functional class, and underwent investigations in the year 2012 in three medical centers in the Republic of Ingushetia. In 2017 patients were invited for second investigation or were contacted by phone. As the primary endpoints the following accounted: revascularization surgery (CBG), endovascular surgery in coronary, carotid, peripheral arteries, diagnosed myocardial infarction, ischemic stroke, diabetes and its complications, fatal outcome from cardiovascular diseases (CVD) and death from other causes. Results. The number of CHD patients with comorbidities was 196, and with no comorbidities — 124. During the follow-up, stroke developed in 17 (5 males, 11 females) patients, myocardial infarction in 37 (20 males, 17 females), diabetes in 38 (15 males, 23 females), fatal CVD outcome in 11 (8 males, 3 females; of those in 5 — acute coronary syndrome, 4 — stroke, 3 — chronic heart failure), and death from other causes in 8 (5 males, 3 females). We also analyzed the development of composite endpoints in CHD patients depending on the presence and absence of comorbidities. Stroke was registered in 13 comorbid patients vs 3 in CHD with no other diseases. Myocardial infarction found in 33 patients with CHD and three comorbidities vs 4 cases in CHD with no comorbidities. Diabetes was found in 32 vs 6 patients, respectively; CVD death in 10 vs 1, resp.; all-cause death in 5 vs 3, resp. Conclusion. Comorbid CHD with 2 and more somatic diseases, during the 5-year period of follow-up, does increase the risk of complications and death from CVD.

Analysis of the clinical efficiency of eradication therapy in patients with coronary heart disease associated with gastroduodenal pathology

To comparatively analyze the clinical efficiency of eradiation therapy (ET) in patients with coronary heart disease (CHD) concurrent with gastroduodenal pathology (GDP). The study was conducted in three steps. In Step 1, 1588 patients with chronic CHD were examined. In Step 2, the characteristics of the course of CHD concurrent with Helicobacter pylori-associated GDP in 147 patients with these conditions compared to the same number of CHD patients without GDP. In Step 3, the impact of a GDP treatment option on the efficiency of treatment was investigated in the patients with CHD. Group 1 received ET + basic therapy (BT); Group 2 used antisecretory therapy + BT; Group 3 consisted of CHD patients without concomitant GDP who received BT only. The time course of changes in clinical and quality-of-life (QOL) indicators was assessed. The patients with CHD concurrent with GDP have a more severe course of the disease as manifested by deterioration in clinical status and QOL. After ET, anginal attack rates were decreased by 62.6% in Group 1, by 30.7% in Group 2 (during antisecretory therapy), and by 29.5% in Group 3. The level of physical QOL increased by 23.7% in Group 1, which was not observed in Groups 2 and 3. Inclusion of ET in an algorithm for treating CHD patients with GDP promotes the angina stability and normalizes QOL in the patients.

Structural and functional state of heart left ventricle depending on polymorphism rs966221 phosphodiesterase 4D gene in emergency workers of the Chornobyl NPP suffering from coronary heart disease

This study consisted in examination the features of structural and functional state of the cardiovascular system in emergency workers (EW) of the Chernobyl nuclear power plant (ChNPP) who suffered from coronary heart disease (CHD) and having different genotypes due to polymorphism rs966221 phosphodiesterase 4D (PDE4D) gene. The study involved 121 EW and 63 non irradiated patients with CHD. Standardized survey included echo doppler cardiography (EchoCG) that was done by Diagnostic Ultrasound System DS N3 (Mindray). Polymorphism rs966221 PDE4D determined by polymerase chain reaction followed by restriction reaction products. The distribution of genotypes PDE4D in EW was as follows: CC - 42, CT - 49 and TT - 30 patients. In the con trol group, carriers of the same genotypes were 27, 21 and 15 persons respectively. All echocardiographic parame ters in EW workers and non irradiated patients did not differ significantly. Amongst TT genotype carriers of both groups the proportion of patients with increased myocardial mass index was the highest (82.9%) compared to CC genotype (78.4%) and CT (71.4%). The concentric type of left ventricular (LV) hypertrophy was found in 54.9% of patients with CC genotype, in 51.8% with CT genotype and 45.7% with TT genotype, while the eccentric type in 23.5, 21.4 and 37.1% respectively. The relative number of people with high LV end diastolic volume (EDV) normalized by body surface area (BSA) was 27.5% in CC genotype carriers, 26.8% in CT genotype and 40% in TT genotype carriers (p > 0.05). The increase of BSA indexed LV end systolic volume (ESV) was found in 27.5, 30.4 and 28.6%, and the ejection fraction in 15.7, 23.2 and 22.9% respectively. The largest number of CHD patients with inadequate dias tolic function was in carriers of TT genotype (75%) compared with the data in CC (66.7%) and CT genotypes (42.9%) carriers. In patients with the same genotype, both EW and non irradiated persons there were virtually no dif ferences in indicators of the structural and functional status of LV. The analysis of changes of LV structure the fol lowing feature was revealed: eccentric type of LV hypertrophy was more common for patients with TT genotype, but concentric type for CC genotype carriers. In one third of patients with CC and CT genotypes and in 40% of TT geno type carriers it was observed LV systolic function disorders. Diastolic dysfunction manifested as often in patients with TT genotype compared with CC and CT genotypes carriers.

Analyzing Recent Coronary Heart Disease Mortality Trends in Tunisia between 1997 and 2009

BackgroundIn Tunisia, Cardiovascular Diseases are the leading causes of death (30%), 70% of those are coronary heart disease (CHD) deaths and population studies have demonstrated that major risk factor levels are increasing.ObjectiveTo explain recent CHD trends in Tunisia between 1997 and 2009.MethodsData Sources: Published and unpublished data were identified by extensive searches, complemented with specifically designed surveys.AnalysisData were integrated and analyzed using the previously validated IMPACT CHD policy model. Data items included: (i)number of CHD patients in specific groups (including acute coronary syndromes, congestive heart failure and chronic angina)(ii) uptake of specific medical and surgical treatments, and(iii) population trends in major cardiovascular risk factors (smoking, total cholesterol, systolic blood pressure (SBP), body mass index (BMI), diabetes and physical inactivity).ResultsCHD mortality rates increased by 11.8% for men and 23.8% for women, resulting in 680 additional CHD deaths in 2009 compared with the 1997 baseline, after adjusting for population change. Almost all (98%) of this rise was explained by risk factor increases, though men and women differed. A large rise in total cholesterol level in men (0.73 mmol/L) generated 440 additional deaths. In women, a fall (−0.43 mmol/L), apparently avoided about 95 deaths. For SBP a rise in men (4 mmHg) generated 270 additional deaths. In women, a 2 mmHg fall avoided 65 deaths. BMI and diabetes increased substantially resulting respectively in 105 and 75 additional deaths. Increased treatment uptake prevented about 450 deaths in 2009. The most important contributions came from secondary prevention following Acute Myocardial Infarction (AMI) (95 fewer deaths), initial AMI treatments (90), antihypertensive medications (80) and unstable angina (75).ConclusionsRecent trends in CHD mortality mainly reflected increases in major modifiable risk factors, notably SBP and cholesterol, BMI and diabetes. Current prevention strategies are mainly focused on treatments but should become more comprehensive.

Increasing evidence-based treatments to reduce coronary heart disease mortality in Sweden: quantifying the potential gains

Between 1986 and 2002, coronary heart disease (CHD) mortality in Sweden fell by more than 50%. Approximately one-third (4800 fewer deaths) of this decline in age-adjusted CHD mortality could be attributed to treatments in patients with CHD and primary prevention medications. High treatment levels were achieved in some cases, but in others, only 50-80% of eligible patients received appropriate therapy. We therefore examined to what extent increasing the use of specific treatments in eligible patients might have reduced CHD mortality rates in Sweden. We used the previously validated IMPACT CHD model to combine data on CHD patient numbers, medical and surgical uptake levels and treatment effectiveness. We estimated the number of deaths prevented or postponed for 2002 (baseline scenario) and for an alternative scenario (if at least 60% of eligible patients were treated). If treatments were increased to consistently cover at least 60% of eligible patients, approximately 8900 deaths could have been postponed or prevented, representing a potential gain of approximately 4100 fewer deaths than actually occurred in 2002. Approximately 45% of the 4100 gain would have come from primary prevention with statins, 23% from acute coronary syndrome treatments, 15% from secondary prevention therapies and 15% from treatments for heart failure. Increasing the proportion of eligible patients with CHD who receive evidence-based treatment could have resulted in approximately 4100 fewer deaths in 2002, almost doubling the actual mortality reduction. These findings further emphasize the importance of aggressively identifying and treating patients with CHD and high-risk individuals.

Potential Reductions in United States Coronary Heart Disease Mortality by Treating More Patients

Approximately one half of the recent decline observed in age-adjusted coronary heart disease (CHD) mortality rates can be attributed to the use of modern medical and surgical interventions. In 2000, however, only about 30% to 60% of eligible patients actually received the appropriate treatment. To examine the reduction in CHD mortality potentially achievable by increasing the provision of specific medical and surgical treatment to eligible patients with CHD in the United States, we integrated the data on CHD patient numbers, medical and surgical treatment uptake levels, and treatment effectiveness using a previously validated CHD policy model. We estimated the number of deaths prevented or postponed for 2000 (baseline) and for an alternative scenario (60% of eligible patients). In 2000, the treatment levels in the United States were generally poor; only 30% to 60% of eligible patients received the appropriate therapy. These treatments resulted in approximately 159,330 fewer deaths. By treating 60% of eligible patients, 297,470 fewer deaths would have been obtained (minimum 118,360; maximum 628,120), representing 134,635 less than in 2000, with approximately 32% from heart failure therapy, 30% from secondary prevention therapy, 19% from acute coronary syndrome treatment, 15% from primary prevention with statins, 0.5% from hypertension treatment, and 1% from coronary bypass surgery for chronic angina. These findings remained stable in the sensitivity analysis. In conclusion, increasing the proportion of eligible patients with CHD who received the appropriate treatment could have achieved approximately 135,000 fewer deaths in 2000, almost doubling the benefit actually achieved. Future strategies should maximize the delivery of appropriate therapies to all eligible patients with CHD and prioritize medical therapies for secondary prevention and heart failure.

Comparing primary prevention with secondary prevention to explain decreasing Coronary Heart Disease death rates in Ireland, 1985–2000

BackgroundTo investigate whether primary prevention might be more favourable than secondary prevention (risk factor reduction in patients with coronary heart disease(CHD)).MethodsThe cell-based IMPACT CHD mortality model was used to integrate data for Ireland describing CHD patient numbers, uptake of specific treatments, trends in major cardiovascular risk factors, and the mortality benefits of these specific risk factor changes in CHD patients and in healthy people without recognised CHD.ResultsBetween 1985 and 2000, approximately 2,530 fewer deaths were attributable to reductions in the three major risk factors in Ireland. Overall smoking prevalence declined by 14% between 1985 and 2000, resulting in about 685 fewer deaths (minimum estimate 330, maximum estimate 1,285) attributable to smoking cessation: about 275 in healthy people and 410 in known CHD patients. Population total cholesterol concentrations fell by 4.6%, resultingin approximately 1,300 (minimum estimate 1,115, maximum estimate 1,660) fewer deaths attributable to dietary changes(1,185 in healthy people and 115 in CHD patients) plus 305 fewer deaths attributable to statin treatment (45 in people without CHD and 260 in CHD patients). Mean population diastolic blood pressure fell by 7.2%, resulting in approximately 170 (minimum estimate 105, maximum estimate 300) fewer deaths attributable to secular falls in blood pressure (140 in healthy people and 30 in CHD patients), plus approximately 70 fewer deaths attributable to antihypertensive treatments in people without CHD.Of all the deaths attributable to risk factor falls, some 1,715 (68%) occurred in people without recognized CHD and 815(32%) in CHD patients.ConclusionCompared with secondary prevention, primary prevention achieved a two-fold larger reduction in CHD deaths. Future national CHD policies should therefore prioritize nationwide interventions to promote healthy diets and reduce smoking.

Prevalence of Anxiety Disorders in Men and Women With Established Coronary Heart Disease

Anxiety has been associated with the development and recurrence of coronary heart disease (CHD). The objective of this study was to estimate the prevalence of anxiety disorders in men and women with established CHD. One hundred fifty CHD patients were evaluated via a semistructured, psychiatric interview to assess both current and lifetime prevalence rates of anxiety disorders. Approximately 36.0% (n = 54) of cardiac patients met the diagnostic criteria for at least 1 current anxiety disorder, and 45.3% (n = 68) presented with an anxiety disorder at some point in their lifetime. Social phobia and generalized anxiety disorder were the most prevalent anxiety disorders observed, with current prevalence rates of 21.3% and 18.7%, respectively, and a lifetime prevalence of 26%. In addition, the current prevalence rate of specific phobia was approximately 14.7%, whereas 15.3% met the lifetime criteria. Lower prevalence rates for panic disorder (current = 4.7%, lifetime = 5.3%), agoraphobia (current = 3.3%, lifetime = 4.7%), posttraumatic stress disorder (current = 0%, lifetime = 1.5%), and obsessive compulsive disorder (current = 0%, lifetime = 0.7%) were observed. Female cardiac patients evidenced significantly higher current (women = 58.3% vs. 25.5%, P < .001) and lifetime (women = 70.8% vs. men = 33.3%, P < .001) rates of anxiety disorders compared with their male counterparts. A considerable number of CHD patients evidence a significant history of anxiety. Greater efforts to identify and treat anxiety in outpatient cardiology and cardiac rehabilitation settings are needed.

The population mortality benefits of maximizing the number of eligible patients receiving appropriate cardiology treatments in Ireland

Coronary heart disease (CHD) mortality rates have been decreasing in many industrialized countries since the 1980s. Up to half this decrease can be attributed to evidence-based medical and surgical cardiology interventions. However, recent studies suggest that modern cardiology treatment uptake levels remain disappointingly low in many patient categories. To determine the potential for further reductions in CHD mortality in Ireland from increasing the number of eligible patients receiving cardiology treatments. A previously validated, cell-based IMPACT CHD mortality model was used to integrate large amounts of data describing CHD patient numbers, and the effectiveness and uptake levels of specific medical and surgical treatments. The CHD mortality reductions potentially achievable through the increased use of specific treatments were then calculated, stratified by age and gender and tested using sensitivity analyses. In 2000, medical and surgical coronary disease treatments together prevented or postponed approximately 1950 CHD deaths in the adult population aged 25-84. However, increasing treatment levels to reach 80% of eligible patients might have prevented or postponed a further 2280 CHD deaths in 2000 (minimum estimate 860, maximum estimate 4000). The biggest gain was from maximizing the treatment uptake of eligible heart failure patients, followed by those receiving statins and secondary prevention therapies. Many eligible patients are currently not receiving appropriate evidence-based treatments that would reduce CHD mortality and morbidity. Our results suggest that increasing cardiology treatment uptake in Ireland could at least double the current therapeutic reduction in CHD mortality.

Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention

Objective To investigate whether population based primary prevention (risk factor reduction in apparently healthy people) might be more powerful than current government initiatives favouring risk factor reduction in patients with...

Prevalence of Depressive Disorders in Men and Women Enrolled in Cardiac Rehabilitation

Epidemiological studies have demonstrated that depression is an independent risk factor for the development and recurrence of coronary heart disease (CHD). The prevalence of depressive disorders, however, is not well documented in CHD patients enrolled in cardiac rehabilitation (CR). The purpose of this study was to estimate the prevalence of current and lifetime depressive disorders in the CR setting. One hundred ten men and women diagnosed with CHD and enrolled in a phase II CR program were screened via a psychiatric, structured interview to assess current and lifetime history of major depressive disorder, minor depression, and dysthymic disorder. A total of 17 (15.5%) individuals screened positive for a current depressive disorder at entry into the CR program, with 10 (9.1%) individuals screening positive for major depressive disorder, 7 (6.4%) for minor depression, and 6 (5.5%) for dysthymic disorder. With respect to lifetime prevalence of mood disorders, 29 (26.4%) individuals met the diagnostic criteria for at least one depressive disorder during their lifetime. The lifetime prevalence of major depressive disorder, minor depression, and dysthymic disorder was 11.8%, 14.5%, and 10.9%, respectively. Female CR participants evidence significantly higher current and lifetime prevalence rates for depressive disorders compared to their male counterparts. The results of this study suggest that a substantial number of CHD patients enrolled in CR report a clinically significant history of depression. Efforts to assess and treat depression are needed in the CR setting and may be associated with better adherence to lifestyle modification programs.

Strategy for primary prevention of coronary heart disease based on results of health check-up

To investigate one of the strategies for effective primary prevention of coronary heart disease (CHD) in employees, the future morbidity of CHD was predicted from the results of an annual health check-up. The decrease in morbidity by measures against coronary risk factors was estimated with simulations. By a CHD risk prediction algorithm based on the Framingham Study, the 10-yr incidence of CHD was predicted in 6,444 male employees of a manufacturing company according to the results of a health check-up in 1998: age, total cholesterol (TC), HDL-cholesterol (HDL-C), blood pressure (BP), diabetes mellitus, and smoking habit. The decrease in CHD incidence obtained by a decrease in TC, increase in HDL-C, decrease in BP, control of diabetes mellitus, or quitting the smoking habit was estimated with simulations by means of the algorithm. The mean +/- SD in 6,444 employees was 45 +/- 11 yr for age; 121 +/- 16 and 79 +/- 10 mmHg for systolic and diastolic BP, respectively; 193 +/- 34, 53 +/- 13, and 98 +/- 18 mg/dl for TC, HDL-C, and fasting blood sugar, respectively; 4.80 +/- 0.58% for HbA1c; and 44% for the frequency of the smoking habit. Among 6,444 males, 455 (7.1%) were predicted to suffer from CHD for 10 yr ahead. If TC was decreased to less than 200 mg/dl in all 2,614 males (N) with TC > or = 200 mg/dl, the decrease (D) in the predicted number of employees with CHD was 64; namely, a reduction of TC to less than 200 mg/dl in 41 males (N/D) with TC > or = 200 mg/dl was estimated to decrease the number of CHD patients by one. Similarly, the D and N/D were 38 and 35 for reduction in BP to less than 140/90 mmHg; 20 and 17 for control of diabetes mellitus; and 90 and 32 for quitting the smoking habit, respectively. A measure against diabetes mellitus was the most effective in respect of N/D, but the predicted total reduction was small (D = 20). On the other hand, a measure against the smoking habit was estimated to have a relatively small N/D as well as the largest D. In 5,386 employees with at least one of the risk factors of TC > or = 200 mg/dl, HDL-C < 45 mg/dl, BP > or = 130/85 mmHg, diabetes mellitus, and the smoking habit, the normalization of all risk factors was estimated to decrease by 230 CHD patients (D = 230, N/D = 23). These results suggest that the strategy for effective primary prevention of CHD in employees of a company should include at first, quitting the smoking habit supported by total prohibition of smoking within company facilities, followed by measures against hyperlipidemia, hypertension and diabetes mellitus.